These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 29452674)

  • 1. Pimavanserin for patients with Alzheimer's disease psychosis.
    Schneider LS
    Lancet Neurol; 2018 Mar; 17(3):194-195. PubMed ID: 29452674
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
    Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
    Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis.
    Ballard CG; Coate B; Abler V; Stankovic S; Foff E
    Int J Geriatr Psychiatry; 2020 Nov; 35(11):1402-1408. PubMed ID: 32729631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
    Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C
    Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson's Disease Psychosis.
    Patel N; LeWitt P; Neikrug AB; Kesslak P; Coate B; Ancoli-Israel S
    Clin Neuropharmacol; 2018; 41(6):210-215. PubMed ID: 30303817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease.
    Price DL; Bonhaus DW; McFarland K
    Behav Pharmacol; 2012 Aug; 23(4):426-33. PubMed ID: 22750845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pimavanserin.
    Hunter NS; Anderson KC; Cox A
    Drugs Today (Barc); 2015 Nov; 51(11):645-52. PubMed ID: 26744739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
    Kianirad Y; Simuni T
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pimavanserin for the treatment of Parkinson's disease psychosis.
    Chendo I; Ferreira JJ
    Expert Opin Pharmacother; 2016 Oct; 17(15):2115-24. PubMed ID: 27609312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychiatric commentary addressing the article titled "Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus".
    Citrome L
    CNS Spectr; 2018 Dec; 23(6):355-357. PubMed ID: 30588903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can pimavanserin help patients with Parkinson disease psychosis?
    de la Cruz J; Canal C
    JAAPA; 2019 Jan; 32(1):44-45. PubMed ID: 30589736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pimavanserin: An Inverse Agonist Antipsychotic Drug.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2016 Jun; 54(6):21-4. PubMed ID: 27245248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
    Sahli ZT; Tarazi FI
    Expert Opin Drug Discov; 2018 Jan; 13(1):103-110. PubMed ID: 29047301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
    Majlath Z; Obal I; Vecsei L
    CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pimavanserin: a new treatment for the Parkinson's disease psychosis].
    Duits JH; Ongering MS; Martens HJM; Schulte PFJ
    Tijdschr Psychiatr; 2017; 59(9):528-536. PubMed ID: 28880354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pimavanserin as treatment for Parkinson's disease psychosis.
    Fox SH
    Lancet; 2014 Feb; 383(9916):494-6. PubMed ID: 24183566
    [No Abstract]   [Full Text] [Related]  

  • 17. Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors.
    Stahl SM
    CNS Spectr; 2016 Aug; 21(4):271-5. PubMed ID: 27503570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pimavanserin and dementia-related psychosis: can HARMONY prevail?
    Liu KY; Howard R
    Lancet Neurol; 2021 Oct; 20(10):783-784. PubMed ID: 34390645
    [No Abstract]   [Full Text] [Related]  

  • 19. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
    Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL
    Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pimavanserin (Nuplazid) for Parkinson's disease psychosis.
    Med Lett Drugs Ther; 2016 Jun; 58(1496):74-5. PubMed ID: 27249096
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.